31 August

Nightstar Files Registration Statement For Proposed Initial Public Offering

LEXINGTON and LONDON – August 31, 2017 – Nightstar Therapeutics Limited (“Nightstar” or the “Company”), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”) representing ordinary shares.

1 August

Nightstar Appoints Tuyen Ong as Chief Development Officer

BOSTON and LONDON – August 1, 2017 — NightstaRx Limited (“Nightstar” or the “Company”), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the appointment of Tuyen Ong, M.D., MRCOphth, MBA, a board-certified ophthalmologist and industry veteran, as executive vice president and chief development officer.

13 July

Nightstar Appoints David Lubner to its Board of Directors

BOSTON and LONDON – July 14, 2017 — NightstaRx Limited (“Nightstar”), a clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced that the company has appointed industry finance veteran David Lubner to its board of directors.

29 June

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

BOSTON & LONDON – June 29th 2017 — NightstaRx Limited (“Nightstar”), a late-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, today announced the completion of a $45 million Series C financing transaction

2 May

NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup to Board of Directors

BOSTON – May 2, 2017 — NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specializing in developing gene therapies for inherited retinal dystrophies, today announced the appointment of Scott M. Whitcup, M.D. to its board of directors.

4 April

NightstaRx Appoints Healthcare Finance Leader Senthil Sundaram as Chief Financial Officer

BOSTON – April 4, 2017 — NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced that Senthil Sundaram has joined the company as Chief Financial Officer.

20 March

NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa

Second NightstaRx AAV Product Candidate in Patient Testing

13 September

NightstaRx Expands Leadership Team, Names Gregory Robinson, Ph.D., as Chief Scientific Officer

LONDON–(BUSINESS WIRE)–NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced that Gregory Robinson, Ph.D., has joined Nightstar as Chief Scientific Officer

28 April

NightstaRx Reports Long-Term Benefits of Gene Therapy for Inherited Form of Progressive Blindness, as Published in the New England Journal of Medicine

London, 28 April 2016 – NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced the publication from the University of Oxford of promising clinical results and long-term benefits of choroideremia gene therapy in this week’s issue of the New England Journal of Medicine (NEJM).

29 February

Preceyes enters into collaborations with NightstaRx (Nightstar) and the University of Oxford to develop subretinal drug delivery technology

Eindhoven, 29 February 2016 – Preceyes B.V. (NL) and Nightstar (UK) have entered into a collaboration for the development of a high-precision drug delivery technology in the eye. Nightstar will use the Preceyes robotic device to further refine the delivery of gene therapy to the subretinal space for a range of inherited retinal diseases. In the course of the collaboration, Nightstar will purchase the PRECEYES Surgical System for use in human gene therapy trials.

12 November

NightstaRx announces the start of a Miami gene therapy study to treat choroideremia

London, 12 November 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in gene therapy for retinal dystrophies, announces that the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has begun enrolling and dosing subjects in a Phase II clinical trial to treat Choroideremia (CHM).

9 November

NightstaRx closes $35 million Series B funding to advance Inherited Retinal Disease pipeline

London, 9 November 2015 – NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round.

29 June

NightstaRx and The University of Alberta announce the start of the first Canadian Gene Therapy Study to Treat Choroideremia

London, 29 June 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, announces that the University of Alberta, has begun enrolling and dosing subjects in a Phase II clinical trial of the Company’s gene therapy for the treatment of choroideremia (CHM).

11 March

Nightstar Receives U.S. and European Orphan Drug Designation for Gene Therapy to Treat Choroideremia

London, 11 January 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, has received both U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Orphan Drug Designation for its lead programme, a gene therapy to treat Choroideremia, an X-linked recessive disorder that leads to progressive blindness.

26 January

Nightstar Announces an Increased Investment to £17m and Appoints a New Chief Executive Officer

NightstaRx Ltd (“Nightstar”), a private biopharmaceutical company specialised in bringing sight improving treatments to patients with retinal dystrophies, announces an increase in its funding to £17 million.

2 July

Nightstar Announces Key Strategic New Hires

NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialised in bringing therapies for retinal dystrophies to patients, announced today that it has made two key strategic new hires with deep ophthalmic experience; David Fellows has been appointed to the Board of Directors and Dr. Aniz Girach has joined the Company as Chief Medical Officer.

30 January

Oxford University and Syncona announce the formation of Nightstar, a company developing retinal gene therapies

Syncona LLP, an independent subsidiary of the Wellcome Trust, announces a £12 million investment in NightstaRx Ltd (“Nightstar”) a spin-out from the University of Oxford and its research commercialisation company Isis Innovation.

MEDIA INQUIRIES
For media inquiries, please contact:
Alicia Davis
THRUST INVESTOR RELATIONS
alicia@thrustir.com
(910) 620-3302